AR122505A1 - Procesos para preparar un inhibidor de jak1 - Google Patents

Procesos para preparar un inhibidor de jak1

Info

Publication number
AR122505A1
AR122505A1 ARP210101500A ARP210101500A AR122505A1 AR 122505 A1 AR122505 A1 AR 122505A1 AR P210101500 A ARP210101500 A AR P210101500A AR P210101500 A ARP210101500 A AR P210101500A AR 122505 A1 AR122505 A1 AR 122505A1
Authority
AR
Argentina
Prior art keywords
prepare
processes
jak1 inhibitor
compound
jak1
Prior art date
Application number
ARP210101500A
Other languages
English (en)
Inventor
Jiacheng Zhou
Yingrui Dai
Zhongjiang Jia
Yongchun Pan
James M Parks
Anthony J Tomaine
Jianji Wang
Aibin Zhang
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AR122505A1 publication Critical patent/AR122505A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/26—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24
    • B01J31/28—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24 of the platinum group metals, iron group metals or copper

Abstract

Reivindicación 1: Un proceso para preparar (base libre del Compuesto 1) o una sal de este, caracterizado porque comprende hacer reaccionar (Compuesto 1x) con (Compuesto 2x) para formar la base libre del Compuesto 1, o una sal de este.
ARP210101500A 2020-06-02 2021-06-02 Procesos para preparar un inhibidor de jak1 AR122505A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063033618P 2020-06-02 2020-06-02

Publications (1)

Publication Number Publication Date
AR122505A1 true AR122505A1 (es) 2022-09-14

Family

ID=76601838

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101500A AR122505A1 (es) 2020-06-02 2021-06-02 Procesos para preparar un inhibidor de jak1

Country Status (18)

Country Link
US (1) US11685731B2 (es)
EP (1) EP4157831A1 (es)
JP (1) JP2023528868A (es)
KR (1) KR20230027086A (es)
CN (1) CN115836065A (es)
AR (1) AR122505A1 (es)
AU (1) AU2021283271A1 (es)
BR (1) BR112022024632A2 (es)
CA (1) CA3184275A1 (es)
CL (1) CL2022003363A1 (es)
CO (1) CO2022017344A2 (es)
CR (1) CR20220612A (es)
EC (1) ECSP22091930A (es)
IL (1) IL298118A (es)
MX (1) MX2022015221A (es)
PE (1) PE20231102A1 (es)
TW (1) TW202210471A (es)
WO (1) WO2021247668A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160126A1 (es) 2013-05-17 2016-02-24 Incyte Corp Derivados del bipirazol como inhibidores jak
SG11202007805SA (en) 2018-02-16 2020-09-29 Incyte Corp Jak1 pathway inhibitors for the treatment of cytokine-related disorders
KR20230118118A (ko) 2020-12-08 2023-08-10 인사이트 코포레이션 백반증의 치료를 위한 jak1 경로 저해제

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CN1321628C (zh) 2000-06-28 2007-06-20 史密斯克莱·比奇曼公司 湿磨方法
DE60230890D1 (de) 2001-09-19 2009-03-05 Aventis Pharma Sa Indolizine als kinaseproteinhemmer
IL161156A0 (en) 2001-10-30 2004-08-31 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
MY162590A (en) 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
EP3495369B1 (en) 2007-06-13 2021-10-27 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
CA2704599C (en) 2007-11-16 2015-05-12 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
SI2288610T1 (sl) 2008-03-11 2016-11-30 Incyte Holdings Corporation Derivati azetidina in ciklobutana kot inhibitorji jak
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
MX2011012262A (es) 2009-05-22 2012-01-25 Incyte Corp 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak).
EA025520B1 (ru) 2009-05-22 2017-01-30 Инсайт Холдингс Корпорейшн N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PT2486041E (pt) 2009-10-09 2013-11-14 Incyte Corp Derivados hidroxilo, ceto e glucuronido de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentil-propanonitrilo
EA023444B1 (ru) 2010-02-18 2016-06-30 Инсайт Холдингс Корпорейшн Циклобутановые и метилциклобутановые производные, композиции на их основе и способы их применения
SI3354652T1 (sl) 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
KR20130094710A (ko) 2010-04-14 2013-08-26 어레이 바이오파마 인크. Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘
SG10201910912TA (en) 2010-05-21 2020-01-30 Incyte Corp Topical Formulation for a JAK Inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
BR112013012502A2 (pt) 2010-11-19 2019-03-06 Incyte Corporation pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
US8828987B2 (en) 2010-12-10 2014-09-09 Rottapharm Biotech S.R.L. Pyridine amide derivatives as EP4 receptor antagonists
US9926601B2 (en) 2011-02-24 2018-03-27 Massachusetts Institute Of Technology Alternatively spliced mRNA isoforms as prognostic indicators for metastatic cancer
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013041042A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Pyrazole carboxamides as janus kinase inhibitors
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
SG10201703533VA (en) 2012-11-01 2017-06-29 Incyte Corp Tricyclic fused thiophene derivatives as jak inhibitors
SG11201503695XA (en) 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
EA030705B1 (ru) 2013-03-06 2018-09-28 Инсайт Холдингс Корпорейшн Способы и промежуточные соединения при получении ингибитора jak
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
PE20160126A1 (es) 2013-05-17 2016-02-24 Incyte Corp Derivados del bipirazol como inhibidores jak
CN105209470B (zh) 2013-05-17 2018-02-06 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的6‑桥连的杂芳基二氢嘧啶
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
ES2792549T3 (es) 2013-08-07 2020-11-11 Incyte Corp Formas de dosificación de liberación sostenida para un inhibidor de JAK1
CN106456773A (zh) 2014-02-28 2017-02-22 因赛特公司 用于治疗骨髓增生异常综合征的jak1抑制剂
AU2015253192B2 (en) 2014-04-30 2019-05-16 Incyte Holdings Corporation Processes of preparing a JAK1 inhibitor and new forms thereto
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US9549916B2 (en) 2014-12-16 2017-01-24 Novartis Ag Isoxazole hydroxamic acid compounds as LpxC inhibitors

Also Published As

Publication number Publication date
TW202210471A (zh) 2022-03-16
IL298118A (en) 2023-01-01
EP4157831A1 (en) 2023-04-05
CN115836065A (zh) 2023-03-21
JP2023528868A (ja) 2023-07-06
CO2022017344A2 (es) 2023-03-07
MX2022015221A (es) 2023-03-08
CR20220612A (es) 2023-04-11
WO2021247668A1 (en) 2021-12-09
AU2021283271A1 (en) 2022-12-15
CA3184275A1 (en) 2021-12-09
US11685731B2 (en) 2023-06-27
PE20231102A1 (es) 2023-07-19
KR20230027086A (ko) 2023-02-27
CL2022003363A1 (es) 2023-05-19
US20210380563A1 (en) 2021-12-09
BR112022024632A2 (pt) 2023-02-28
ECSP22091930A (es) 2023-02-28

Similar Documents

Publication Publication Date Title
AR122505A1 (es) Procesos para preparar un inhibidor de jak1
CO2022002637A2 (es) Proceso de fabricación de moduladores de cftr
CL2020000407A1 (es) Proceso para preparar compuesto inhibidor de bet. (solicitud divisional 201803702).
AR118707A1 (es) Inhibidores de la proteasa del vih
AR111960A1 (es) Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
AR105434A1 (es) Proceso para preparar pridopidina
EA202193015A1 (ru) Ингибиторы cdk
ECSP23019419A (es) Proceso e intermedios para preparar un inhibidor de jak1
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
CY1121885T1 (el) Αντι-ογκικες ενωσεις
CO2018007008A2 (es) "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo"
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
MX2021011753A (es) Degradadores de moleculas peque?as de stat3.
AR116951A1 (es) Sales cristalinas de un inhibidor de calicreína plasmática
CL2023001367A1 (es) Inhibidores de btk
CO2023003281A2 (es) Proceso e intermediarios para preparar un inhibidor de jak
MX2020011671A (es) Nuevo proceso para la preparacion de diamidas antranilicas.
MX2023000970A (es) Metodo de preparacion de aminofuranos.
UY39832A (es) Inhibidores de cdk2
AR107163A1 (es) Inhibidores de quinasa
WO2020128020A3 (de) Verfahren zur herstellung von 2-alkoxy-4-amino-5-methyl-pyridinen und/oder von 2-alkoxy-4-alkylamino-5-methyl-pyridinen
CL2022001511A1 (es) Procesos e intermediario para la preparación de oxetan-2-ilmetanamina
MX2023006157A (es) Mediadores lipidicos proresolutivos especializados para el tratamiento del pcos.
AR117014A1 (es) Proceso para la síntesis de lactamas
MX2021013726A (es) Butirato alimentario y sus usos.